The U.S. House Appropriations Committee has advanced a Fiscal Year 2027 spending bill that explicitly bars federal workers' compensation programs from covering medical marijuana expenses.
The legislation, which covers the Department of Labor and the Department of Health and Human Services, includes a provision ensuring that even if the federal government successfully moves forward with the rescheduling of cannabis from Schedule I to Schedule III, the specific prohibition on workers' compensation coverage for medical marijuana would remain in effect. This legislative move signals a continued resistance within certain congressional circles to fully integrate cannabis into federal healthcare or benefits frameworks, despite the ongoing executive branch efforts to modify the scheduling status of the plant. For stakeholders in the cannabis industry, this development highlights the persistent regulatory friction between federal administrative shifts and legislative budget mandates.
While the Biden-Harris administration has championed rescheduling as a path toward broader reform, the Appropriations Committee’s move demonstrates that federal agencies may continue to face statutory roadblocks that prevent the recognition of cannabis as a legitimate medical treatment for work-related injuries. Industry analysts suggest that this policy will likely result in continued out-of-pocket expenses for federal employees who utilize cannabis for therapeutic purposes, potentially suppressing the growth of medical cannabis utilization within the federal workforce sector. Furthermore, the inclusion of this language in an appropriations bill suggests that fiscal policy, rather than just drug policy, is being utilized to maintain current restrictive practices regarding cannabis access.
As this bill moves through the legislative process, dispensary operators and medical cannabis brands should monitor how these federal funding constraints might influence state-level insurance mandates and employer-provided benefit packages in the long term.